Intervention

Ivabradine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 22 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials22

Recruiting0

Common conditions25

Lead sponsors shown15

Clinical trials

22 shown

Ivabradine in Stage D Heart Failure Patients on Chronic InotropesNCT03631654 · 2020-10-01

Ivabradine to Prevent Anthracycline-induced CardiotoxicityNCT04030546 · 2019-06-01

Ivabradine to Prevent Anthracycline-induced CardiotoxicityNCT03650205 · 2019-01-22

Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-BlockerNCT03830957 · 2018-11-26

Early Use of Ivabradine in Heart FailureNCT03701880 · 2018-09-16

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation UnitNCT03168529 · 2018-07-01

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on DobutamineNCT03387605 · 2018-03-15

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.NCT03456856 · 2017-09-28

IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart DiseaseNCT03105219 · 2017-07-01

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure PatientsNCT03710057 · 2016-12-01

Pulse Reduction On Beta-blocker and Ivabradine TherapyNCT02973594 · 2016-11-01

The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.NCT02247245 · 2014-09-01

Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization TherapyNCT02166060 · 2014-08-01

Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection FractionNCT02046044 · 2014-01-01

If Channel Blockade With Ivabradine in Patients With Diastolic Heart FailureNCT00757055 · 2012-12-01

The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)NCT02354573 · 2011-12-01

Ivabradine in Hemodialysed Patients With Increased Heart RateNCT01364077 · 2010-01-01

Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of IvabradineNCT01373619 · 2010-01-01

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart FailureNCT02446990 · 2009-09-01

Efficacy Study of Digoxin & Ivabradine to Treat Heart FailureNCT01699776 · 2008-04-01

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre StudyNCT02441218 · 2006-09-01

Efficacy and Safety of Ivabradine in Severe Congestive Heart FailureNCT00202579 · 2004-09-01

Common conditions

Leading sponsors

Institut de Recherches Internationales Servier 3 University of Campania Luigi Vanvitelli 2 Ain Shams University 1 Amgen 1 Cocco, Giuseppe, M.D. 1 Getz Pharma 1 Kocaeli University 1 Loyola University 1 Medical University of Warsaw 1 Nanjing First Hospital, Nanjing Medical University 1 Phillip Levy 1 Rajaie Cardiovascular Medical and Research Center 1 St Vincent's University Hospital, Ireland 1 University of Colorado, Denver 1 University of Leeds 1

Trial status mix

COMPLETED10

UNKNOWN8

WITHDRAWN3

TERMINATED1

Phase mix

PHASE410

NA5

PHASE34

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.